Preprint / Version 1

Unveiling the Hidden Dangers of Iron Overload - A Systematic Review

##article.authors##

  • Selim Eke Interlake High School

DOI:

https://doi.org/10.58445/rars.2074

Abstract

Iron deficiency, the leading cause of anemia, has fueled a dramatic rise in the consumption of
iron supplements, yet the dangers of iron overload remain largely unrecognized. Iron overload,
though less discussed than iron deficiency, can silently wreak havoc on the body, leading to
significant organ damage if left unchecked. Excess iron, whether from frequent transfusions,
supplements, or genetic conditions like hereditary hemochromatosis, accumulates in vital
organs such as the liver, heart, and pancreas. Over time, this build-up can cause irreversible
damage, including liver fibrosis, heart failure, and endocrine dysfunction. This review explores
the complex pathways through which iron overload affects various organs, highlighting its role in
the development of chronic diseases like cirrhosis, cardiomyopathy, and diabetes. As iron
excess often goes unnoticed until severe symptoms arise, early detection and targeted
treatment strategies are crucial to preventing long-term damage. By understanding the
underlying mechanisms and health impacts, this review emphasizes the need for timely
intervention in at-risk populations to mitigate the hidden dangers of iron overload.

References

Tian Y, Tian Y, Yuan Z, Zeng Y, Wang S, Fan X, Yang D, Yang M. Iron Metabolism in

Aging and Age-Related Diseases. Int J Mol Sci. 2022 Mar 25;23(7):3612. doi:

3390/ijms23073612. PMID: 35408967; PMCID: PMC8998315.

GBD 2021 Anaemia Collaborators. Prevalence, years lived with disability, and trends in

anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease

Study 2021. Lancet Haematol. 2023 Sep;10(9):e713-e734. doi: 10.1016/S2352-3026(23)00160

Epub 2023 Jul 31. Erratum in: Lancet Haematol. 2023 Oct;10(10):e796. doi: 10.1016/S2352

(23)00283-1. Erratum in: Lancet Haematol. 2024 Jan;11(1):e10. doi: 10.1016/S2352

(23)00373-3. PMID: 37536353; PMCID: PMC10465717.

Shander A, Cappellini, M.D., Goodnough L.T. Iron overload and toxicity: the hidden risk of

multiple blood transfusions, The International Journal of Transfusion Medicine Vox Sanguinis

-97-185-197

Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of

Mammalian iron metabolism. Cell. 2010 Jul 9;142(1):24-38. doi: 10.1016/j.cell.2010.06.028.

PMID: 20603012.

Wang K, Yang F, Zhang P, Yang Y, Jiang L. Genetic effects of iron levels on liver injury

and risk of liver diseases: A two-sample Mendelian randomization analysis. Front Nutr. 2022

Sep 16;9:964163. doi: 10.3389/fnut.2022.964163. PMID: 36185655; PMCID: PMC9523310.

Khonsary SA. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Surg

Neurol Int. 2023 Mar 17;14:91. doi: 10.25259/SNI_184_2023. PMCID: PMC10070253.

Harrison-Findik, Role of alcohol in the regulation of iron metabolism World J Gastroenterol

October 7; 13(37): 4925-4930.

Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, Imashuku S, Ladisch

S, Webb D, Janka G, Henter JI; Histiocyte Society. Chemoimmunotherapy for hemophagocytic

lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011 Oct

;118(17):4577-84. doi: 10.1182/blood-2011-06-356261. Epub 2011 Sep 6. PMID: 21900192;

PMCID: PMC3208276.

Hankins JS, Smeltzer MP, McCarville MB, Aygun B, Hillenbrand CM, Ware RE, Onciu M.

Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron

overload. Eur J Haematol. 2010 Jul;85(1):51-7. doi: 10.1111/j.1600-0609.2010.01449.x. Epub

Mar 31. PMID: 20374273; PMCID: PMC2989598.

Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):265-271. doi:

1182/asheducation-2017.1.265. PMID: 29222265; PMCID: PMC6142532.

Pilo F, Cilloni D, Della Porta MG, Forni GL, Piperno A, Santini V, Angelucci E. Iron

mediated tissue damage in acquired ineffective erythropoiesis disease: It's more a matter of

burden or more of exposure to toxic iron form? Leuk Res. 2022 Mar;114:106792. doi:

1016/j.leukres.2022.106792. Epub 2022 Jan 21. PMID: 35091283.

Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative

mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003 Apr

;101(7):2461-3. doi: 10.1182/blood-2002-10-3235. Epub 2002 Nov 14. PMID: 12433676.

Naito Y, Masuyama T, Ishihara M. Iron and cardiovascular diseases. J Cardiol. 2021

Feb;77(2):160-165. doi: 10.1016/j.jjcc.2020.07.009. Epub 2020 Jul 30. PMID: 32739111.

Zeidan RS, Han SM, Leeuwenburgh C, Xiao R. Iron homeostasis and organismal aging.

Ageing Res Rev. 2021 Dec;72:101510. doi: 10.1016/j.arr.2021.101510. Epub 2021 Nov 9.

PMID: 34767974; PMCID: PMC8620744.

Peslova G, Petrak J, Kuzelova K, Hrdy I, Halada P, Kuchel, W. Soe-Lin, S. Ponka, P. Sutak

R. Becker E. et al. Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2

macrglobulin in blood. Blood. 2009; 113:6225-6236.

Bruzzese A, Martino EA, Mendicino F, Lucia E, Olivito V, Bova C, Filippelli G, Capodanno I,

Neri A, Morabito F, Gentile M, Vigna E. Iron chelation therapy. Eur J Haematol. 2023

May;110(5):490-497. doi: 10.1111/ejh.13935. Epub 2023 Feb 8. PMID: 36708354.

Frazer DM, Wilkins SJ, Vulpe CD, Anderson GJ. The role of duodenal cytochrome b in

intestinal iron absorption remains unclear. Blood. 2005 Dec 15;106(13):4413; author reply 4414.

doi: 10.1182/blood-2005-07-2923. PMID: 16326980; PMCID: PMC1895251.

Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, Hershko C, Cappellini

MD. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J

Hematol. 2009 Jan;84(1):29-33. doi: 10.1002/ajh.21317. PMID: 19006228.

Kouroumalis E, Tsomidis I, Voumvouraki A. Iron as a therapeutic target in chronic liver

disease. World J Gastroenterol. 2023 Jan 28;29(4):616-655. doi: 10.3748/wjg.v29.i4.616. PMID:

; PMCID: PMC9896614.

Le Lan C, Loréal O, Cohen T, Ropert M, Glickstein H, Lainé F, Pouchard M, Deugnier Y, Le

Treut A, Breuer W, Cabantchik ZI, Brissot P. Redox active plasma iron in C282Y/C282Y

hemochromatosis. Blood. 2005 Jun 1;105(11):4527-31. doi: 10.1182/blood-2004-09-3468. Epub

Jan 25. PMID: 15671444.

Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: Mechanistic and clinical aspects.

World J Gastroenterol. 2019 Feb 7;25(5):521-538. doi: 10.3748/wjg.v25.i5.521. PMID:

; PMCID: PMC6371002.

Pootrakul P, Breuer W, Sametband M, et al. Labile plasma iron (LPI) as an indicator of

chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with

an oral chelator. Blood 2004;104:1504-1510.

Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, Yazdanpanah M, Wilson

GJ, Schwartz A, Liu PP, Backx PH. L-type Ca2+ channels provide a major pathway for iron

entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003 Sep;9(9):1187-94.

doi: 10.1038/nm920. Epub 2003 Aug 24. PMID: 12937413.

Keiko Matsui, Sachiko Ezoe, Takafumi Yokota, Tomohiko Ishibashi, Kenji Oritani, Yuzuru

Kanakura; Iron Overload Effects On Immune System Through The Cytokine Secretion By

Macrophage. Blood 2013; 122 (21): 1047

Ning S, Zeller MP. Management of iron deficiency. Hematology Am Soc Hematol Educ

Program. 2019 Dec 6;2019(1):315-322. doi: 10.1182/hematology.2019000034. PMID:

; PMCID: PMC6913441.

Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy:

clinical and pathophysiological insights. Int J Hematol. 2018 Jan;107(1):16-30. doi:

1007/s12185-017-2373-3. Epub 2017 Dec 1. PMID: 29196967.

Düzen Oflas N, Demircioğlu S, Yıldırım Doğan N, Eker E, Kutlucan A, Doğan A, Aslan M,

Demir C. Comparison of the effects of oral iron treatment every day and every other day in

female patients with iron deficiency anaemia. Intern Med J. 2020 Jul;50(7):854-858. doi:

1111/imj.14766. PMID: 31994303.

Richards T, Breymann C, Brookes MJ, Lindgren S, Macdougall IC, McMahon LP, Munro

MG, Nemeth E, Rosano GMC, Schiefke I, Weiss G. Questions and answers on iron deficiency

treatment selection and the use of intravenous iron in routine clinical practice. Ann Med. 2021

Dec;53(1):274-285. doi: 10.1080/07853890.2020.1867323. PMID: 33426933; PMCID:

PMC7877947.

Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron

preparations. Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012.

PMID: 24310424; PMCID: PMC3857035.

Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between

hepatocellular injury and transfusional iron overload prior to and during iron chelation with

desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003 Jan 1;101(1):91

doi: 10.1182/blood-2002-06-1704. Epub 2002 Aug 22. PMID: 12393528.

Saliba A, Taher A. Iron overload in transfusion-dependent thalassemia. Hematology. 2015

Jun;20(5):311-2. doi: 10.1179/1024533215Z.000000000365. PMID: 25967377.

Vinchi F, Porto G, Simmelbauer A, Altamura S, Passos ST, Garbowski M, et al.

Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological

iron restriction. Eur Heart J 2019; (MARCH].

Vinchi F, Muckenthaler MU, Da Silva MC, Balla G, Balla J, Jeney V. Atherogenesis and

iron: from epidemiology to cellular level. Front Pharmacol 2014;5:94.

Maciej W. Garbowski, Amna Abdel-Gadir, James Moon, John B. Porter; Myocardial

Hemosiderosis Correlates with Plasma NTBI Species That Represent Chelated Iron in

Transfusion-Dependent Thalassemia. Blood 2016; 128 (22): 203.

Noetzli LJ, Coates TD, Wood J, Pancreatic iron loading in chronically transfused sickle cell

disease is lower than in thalassemia major, Br J Haematol. 2011;152(2):229. Epub 2010 Dec 1.

Jensen PD. Evaluation of iron overload. Br J Haematol. 2004 Mar;124(6):697-711. doi:

1111/j.1365-2141.2004.04838.x. PMID: 15009057.

Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J, Forman SJ. Iron overload

adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow

Transplant. 2008 Dec;42(12):799-805. doi: 10.1038/bmt.2008.262. Epub 2008 Sep 1. PMID:

Mwangi MN, Mzembe G, Moya E, Verhoef H. Iron deficiency anaemia in sub-Saharan

Africa: a review of current evidence and primary care recommendations for high-risk groups.

Lancet Haematol. 2021 Oct;8(10):e732-e743. doi: 10.1016/S2352-3026(21)00193-9. Epub 2021

Sep 2. PMID: 34481549.

Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of

inflammation. Blood. 2003 Aug 1;102(3):783-8. doi: 10.1182/blood-2003-03-0672. Epub 2003

Mar 27. PMID: 12663437.

Kortman, G.A.M.; Boleij, A.; Swinkels, D.W.; Tjalsma, H. Iron Availability Increases the

Pathogenic Potential of Salmonella Typhimurium and Other Enteric Pathogens at the Intestinal

Epithelial Interface. PLoS ONE 2012, 7, e29968.

Ghanchi A, James PT, Cerami C. Guts, Germs, and Iron: A Systematic Review on Iron

Supplementation, Iron Fortification, and Diarrhea in Children Aged 4-59 Months. Curr Dev Nutr.

Jan 15;3(3):nzz005. doi: 10.1093/cdn/nzz005. PMID: 30891538; PMCID: PMC6416531.

Jaeggi T, Kortman GA, Moretti D, Chassard C, Holding P, Dostal A, Boekhorst J,

Timmerman HM, Swinkels DW, Tjalsma H, Njenga J, Mwangi A, Kvalsvig J, Lacroix C,

Zimmermann MB. Iron fortification adversely affects the gut microbiome, increases pathogen

abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015 May;64(5):731-42.

doi: 10.1136/gutjnl-2014-307720. Epub 2014 Aug 20. PMID: 25143342.

Paganini D, Zimmermann MB. The effects of iron fortification and supplementation on the

gut microbiome and diarrhea in infants and children: a review. Am J Clin Nutr. 2017

Dec;106(Suppl 6):1688S-1693S. doi: 10.3945/ajcn.117.156067. Epub 2017 Oct 25. PMID:

; PMCID: PMC5701709.

Hintze KJ, Theil EC. DNA and mRNA elements with complementary responses to hemin,

antioxidant inducers, and iron control ferritin-L expression. Proc Natl Acad Sci USA 2005;

:15048.

McDowell LA, Kudaravalli P, Chen RJ, Sticco KL. Iron Overload. 2024 Jan 11. In:

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30252387.

Cullis JO, Fitzsimons EJ, Griffiths WJ, Tsochatzis E, Thomas DW; British Society for

Haematology. Investigation and management of a raised serum ferritin. Br J Haematol. 2018

May;181(3):331-340. doi: 10.1111/bjh.15166. Epub 2018 Apr 19. PMID: 29672840.

Puliyel M, Sposto R, Berdoukas VA, Hofstra TC, Nord A, Carson S, Wood J, Coates TD.

Ferritin trends do not predict changes in total body iron in patients with transfusional iron

overload. Am J Hematol. 2014 Apr;89(4):391-4. doi: 10.1002/ajh.23650. Epub 2014 Feb 28.

PMID: 24347294.

Pakbaz Z, Fischer R, Fung E, Nielsen P, Harmatz P, Vichinsky E. Serum ferritin

underestimates liver iron concentration in transfusion independent thalassemia patients as

compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer.

Sep;49(3):329-32. doi: 10.1002/pbc.21275. PMID: 17554789.

Tang H, Jensen JH, Sammet CL, Sheth S, Swaminathan SV, Hultman K, Kim D, Wu EX,

Brown TR, Brittenham GM. MR characterization of hepatic storage iron in transfusional iron

overload. J Magn Reson Imaging. 2014 Feb;39(2):307-16. doi: 10.1002/jmri.24171. Epub 2013

May 29. PMID: 23720394; PMCID: PMC3761000.

Wood JC. Use of magnetic resonance imaging to monitor iron overload. Hematol Oncol Clin

North Am. 2014 Aug;28(4):747-64, vii. doi: 10.1016/j.hoc.2014.04.002. PMID: 25064711;

PMCID: PMC4115249.

Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B,

Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early

diagnosis of myocardial iron overload. Eur Heart J. 2001 Dec;22(23):2171-9. doi:

1053/euhj.2001.2822. PMID: 11913479.

Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, Golden D, Neumayr L,

Vichinsky E. Severity of iron overload in patients with sickle cell disease receiving chronic red

blood cell transfusion therapy. Blood. 2000 Jul 1;96(1):76-9. PMID: 10891433.

Christopher Grant, Dennis Juarez, Zahra Pakbaz; Iron Overload in Dialysis Patients: Serum

Ferritin Underestimates Liver Iron Measured By MRI. Blood 2023; 142 (Supplement 1): 5241

Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure

treated by hemodialysis. Am J Kidney Dis. 2013 Jun;61(6):992-1000. doi:

1053/j.ajkd.2012.10.027. Epub 2013 Jan 31. PMID: 23375852.

Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, Kushnir T, Girelli

D, Campostrini N, Fibach E, Goitein O. Evidence for tissue iron overload in long-term

hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012

Jul;89(1):87-93. doi: 10.1111/j.1600-0609.2012.01783.x. Epub 2012 May 18. PMID: 22435497.

Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado

G, Janklewicz P, Drahi G, Dahan H, Cohen Y. Hemodialysis-associated hemosiderosis in the

era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012 Oct;125(10):991-999.e1.

doi: 10.1016/j.amjmed.2012.01.015. PMID: 22998881.

Yesim Aydinok, Antonis Kattamis, M Domenica Cappellini, Amal El-Beshlawy, Raffaella

Origa, Mohsen Elalfy, Yurdanur Kilinç, Silverio Perrotta, Zeynep Karakas, Vip Viprakasit, Dany

Habr, Antje Wegener, Junwu Shen, John B Porter; on behalf of the HYPERION investigators,

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron

Removal In Patients With Severe Transfusional Iron Overload (HYPERION). Blood 2013; 122

(21): 2257.

Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG.

Hemochromatosis mutations in the general population: iron overload progression rate. Blood.

Apr 15;103(8):2914-9. doi: 10.1182/blood-2003-10-3564. Epub 2003 Dec 4. PMID:

Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010 Jul 22;116(3):317-25.

doi: 10.1182/blood-2010-01-261875. Epub 2010 Mar 22. PMID: 20308595.

Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G,

Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J

Med. 1994 Sep 1;331(9):574-8. doi: 10.1056/NEJM199409013310903. PMID: 8047081.

Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of

death in adult sickle cell disease patients. Am J Hematol. 2006 Nov;81(11):858-63. doi:

1002/ajh.20685. PMID: 16924640.

Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with

sickle cell disease. Semin Hematol. 2001 Jan;38(1 Suppl 1):30-6. doi: 10.1016/s0037

(01)90058-7. PMID: 11206959.

Guillermo Sanz, Benet Nomdedeu, Esperanza Such, Teresa Bernal, Mohamed Belkaid, Ma

Teresa Ardanaz, Victor Marco, Carme Pedro, Fernando Ramos, Maria Consuelo del Cañizo,

Elisa Luño, Francesc Cobo, Felix Carbonell, Valle Gomez, Juan A Muñoz, Mari Luz Amigo,

Alicia Bailen, Santiago Bonanad, Mar Tormo, Rafael Andreu, Beatriz Arrizabalaga, Maria J.

Arilla, Javier Bueno, Maria J. Requena, Joan Bargay, Joaquin Sanchez, Leonor Senent, Leonor

Arenillas, Raquel de Paz, Blanca Xicoy, Rafael Duarte, Jose Cervera; Independent Impact of

Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with

Myelodysplastic Syndrome. Blood 2008; 112 (11): 640.

Downloads

Posted

2024-12-17

Categories